Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Celecoxib · Celebrex, Vyscoxa

Small molecule · Inhibitor of Cyclooxygenase-2 (PTGS2) · developed by Gd Searle Llc

Approved FDA, Dec 1999
1 Registered trials

What is Celecoxib?

Celecoxib is a nonsteroidal anti-inflammatory drug that inhibits prostaglandin synthesis, primarily by inhibiting COX-2, reducing prostaglandin-mediated pain and inflammation in peripheral tissues. It is studied in osteoarthritis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Celebrex, Vyscoxa, DFN-15, NSC-719627
Drug type
Small molecule
Targets
Cyclooxygenase-2 (PTGS2)
Mechanism
Inhibitor of Cyclooxygenase-2 (PTGS2)
Pathways
prostaglandin synthesis, inflammation
Therapy area
Musculoskeletal
Developer
Gd Searle Llc
In trials of
OGN
FDA status
Approved as Celebrex, Vyscoxa (December 23, 1999), NDA021156 · FDA label
UNII
JCX84Q7J1L

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 31, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00092781 Phase 3 Osteoarthritis Completed OGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Osteoarthritis

Other drugs acting on PTGS2

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.